Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes.
about
Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemicType 2 diabetes as a disease of ectopic fat?Effect of pioglitazone on energy intake and ghrelin in diabetic patients.Pioglitazone treatment reduces adipose tissue inflammation through reduction of mast cell and macrophage number and by improving vascularity.Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.Template to improve glycemic control without reducing adiposity or dietary fat.Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetesSex-Specific Association between Serum Uric Acid and Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Patients.Review of approved pioglitazone combinations for type 2 diabetes.Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies.Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis.Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial.A diet formula of Puerariae radix, Lycium barbarum, Crataegus pinnatifida, and Polygonati rhizoma alleviates insulin resistance and hepatic steatosis in CD-1 mice and HepG2 cells.
P2860
Q24563381-37B0F375-D6BC-4C54-B598-8137A48B589AQ27022915-92EDF94E-D0CD-427D-B894-C70B35D8973BQ33751453-FAD6DC9E-5C70-4F77-AF6B-9E987FAFD669Q33882669-A3B393D2-72AC-4B27-82F9-CA2D63EBE3B0Q34168532-769CFEB5-359B-4B92-960E-19BDEB1EDAD3Q34979386-786D087D-28E8-4E4E-85B7-5270935F4E9EQ36632132-A3269225-84C9-4B2A-9F3A-ADB99DCDE43CQ37038253-1A9FC356-2C8B-4B01-80A2-37D21E3F5497Q37884618-DAD19BA5-D6D9-46EC-9395-D27A7A2E49C3Q37978785-A687922D-AC72-4D4A-A090-A59DEED9C9A3Q38550285-69B648AE-D926-45FA-A99D-70C9EAC6CC84Q38588541-810E08A1-0BEC-4AA0-BE22-51B68C01FBBFQ38645244-DB1E8C22-616D-4709-A2BE-89822631B945Q45340364-D1E7488B-7709-44A1-932A-931D7D28384CQ51325717-6283EEEF-764D-487F-B4E6-22C3C89220F0
P2860
Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Pioglitazone, but not metformi ...... independent of weight changes.
@ast
Pioglitazone, but not metformi ...... independent of weight changes.
@en
type
label
Pioglitazone, but not metformi ...... independent of weight changes.
@ast
Pioglitazone, but not metformi ...... independent of weight changes.
@en
prefLabel
Pioglitazone, but not metformi ...... independent of weight changes.
@ast
Pioglitazone, but not metformi ...... independent of weight changes.
@en
P2093
P2860
P1476
Pioglitazone, but not metformi ...... independent of weight changes
@en
P2093
Corby K Martin
Frank L Greenway
George A Bray
Steven R Smith
P2860
P304
P356
10.1016/J.JDIACOMP.2009.05.004
P577
2009-07-04T00:00:00Z